02 Apr , 2026 By : Debdeep Gupta
Lupin share price slipped 2.5 percent in the opening trade on April 2 after the company announced that its subsidiary will acquire a minority stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI).
At 09:18am, Lupin was quoting at Rs 2,216.20, down Rs 57.40, or 2.52 percent, on the BSE.
In an exchange filing, the company said its wholly owned subsidiary, Nanomi B.V., Netherlands, has entered into definitive agreements to acquire 11,794,497 shares—representing a 43.38% stake—in MPPI from existing shareholders. The acquisition, valued at up to $39.6 million, is expected to be completed by the end of May 2026, subject to closing conditions.
In a separate development, the company informed that Nanomi has completed the full acquisition of VISUfarma B.V., Netherlands. Consequently, VISUfarma and its subsidiaries have become wholly owned subsidiaries of Nanomi effective April 1, 2026.
Last month, Lupin received tentative approvals from the US Food and Drug Administration (USFDA) for Sugammadex Injection and Pitolisant Tablets, strengthening its pipeline. The Pitolisant tablets will be manufactured at the company’s Nagpur facility.
In the previous trading session, the stock closed at ?2,273.60, down ?39.10 or 1.69%. The stock has touched a 52-week high of ?2,376 and a low of ?1,774. It is currently trading 4.31?low its 52-week high and 28.16?ove its 52-week low.
The company’s market capitalisation stands at ?1.04 lakh crore
0 Comment